/0	1 -	E \	
NOV		2003	20
	ι	Jnder ti	he Bap

BACEWAEN

11-26-03

PTO/SB/30 (08-03)

Approved for use through 07/31/2006. OMB 0651-008

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR

CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	09/771,536
Filing Date	January 29, 2001
First Named Inventor	LANGRIDGE, William H.R.
Art Unit	1648
Examiner Name	HILL, Myron G.
Attorney Docket Number	12273-3

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June

8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.					
1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such					
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on ii. Other b. Enclosed i. Amendment/Reply iii. Information Disclosure Statement (IDS) iii. Affidavit(s)/Declaration(s) iv. Other					
	. , , , , , , , , , , , , , , , , , , ,	Information Disclosu Other	re Statement (IDS)	- Congression	
 2. Miscellaneous a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) b. ☐ Other 					
 3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 19-2090 i. RCE fee required under 37 CFR 1.17(e) ii. Extension of time fee (37 CFR 1.136 and 1.17) iii. Other 					
b. Check in the amount of \$ enclosed c. Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
Name (Print / Type)	David A. Farah, M.D.	Registr	ation No. (Attorney / Agent)	38,134	
Signature	Dad Fand	Date	November 24, 2003		
CERTIFICATE OF MAILING OR TRANSMISSION					
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.					
Name (Print / Type)	Marilyn Paik	VIA EXPR	ESS MAI		
Signature	Markes	Date	November 24, 2003	<i></i>	
This collection of information is	required by 37 CFR 1.114. The information is	required to obtain or retain a	benefit by the public which	is to file (and by the USPTO to	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

12273-3

OIP &	IN THE UNITED STATES PATE	ENT AND TRADEMARK OFFICE
RAC BAC) Group Art Unit: 1648
	LANGRIDGE, William H.R. et al.	Examiner: HILL, Myron G.
	Serial No. 09/771,536	Confirmation No.: 9620
	Filing Date: January 29, 2001))
	For: Transgenic Plant-Based Vaccines) Pasadena, California)

RESPONSE AND AMENDMENT

Mail Stop RCE Commissioner for Patents Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated July 29, 2003, please amend the above-identified United States patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.